floxuridine + oxaliplatin

Floxuridine + oxaliplatin is a combination of two chemotherapeutic agents used primarily in the treatment of unresectable liver metastases from colorectal cancer. Floxuridine is an antimetabolite that is metabolized to fluorouracil, inhibiting DNA synthesis by interfering with thymidylate synthase. Oxaliplatin is a platinum-based compound that forms DNA crosslinks, leading to apoptosis in rapidly dividing cells. This combination can be administered via hepatic arterial infusion (HAI) for floxuridine and systemic administration for oxaliplatin, often as part of multi-drug regimens or alternating schedules with other agents such as capecitabine or 5-fluorouracil. The regimen has demonstrated high response rates in hepatic metastases and manageable toxicity profiles[1][3][4].

Other names

fluorodeoxyuridine and oxaliplatinFdUrd + oxaliplatin